CERE
Morgan Stanley’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-330,728
| Closed | -$13.5M | – | 8124 |
|
|
2024
Q2 | $13.5M | Sell |
330,728
-182,763
| -36% | -$7.47M | ﹤0.01% | 3074 |
|
|
2024
Q1 | $21.7M | Sell |
513,491
-998,413
| -66% | -$42.2M | ﹤0.01% | 2607 |
|
|
2023
Q4 | $64.1M | Buy |
1,511,904
+1,428,265
| +1,708% | +$60.6M | ﹤0.01% | 2189 |
|
|
2023
Q3 | $1.83M | Sell |
83,639
-77,061
| -48% | -$1.68M | ﹤0.01% | 4444 |
|
|
2023
Q2 | $5.11M | Sell |
160,700
-60,064
| -27% | -$1.91M | ﹤0.01% | 3765 |
|
|
2023
Q1 | $5.38M | Sell |
220,764
-330,713
| -60% | -$8.07M | ﹤0.01% | 3727 |
|
|
2022
Q4 | $17.4M | Buy |
551,477
+50,520
| +10% | +$1.59M | ﹤0.01% | 2487 |
|
|
2022
Q3 | $14.2M | Buy |
500,957
+115,673
| +30% | +$3.27M | ﹤0.01% | 2584 |
|
|
2022
Q2 | $10.2M | Buy |
385,284
+279,674
| +265% | +$7.39M | ﹤0.01% | 3047 |
|
|
2022
Q1 | $3.7M | Buy |
105,610
+62,695
| +146% | +$2.19M | ﹤0.01% | 4004 |
|
|
2021
Q4 | $1.39M | Buy |
42,915
+16,837
| +65% | +$546K | ﹤0.01% | 4852 |
|
|
2021
Q3 | $768K | Buy |
26,078
+10,551
| +68% | +$311K | ﹤0.01% | 5226 |
|
|
2021
Q2 | $397K | Buy |
15,527
+10,227
| +193% | +$261K | ﹤0.01% | 5671 |
|
|
2021
Q1 | $73K | Sell |
5,300
-9,086
| -63% | -$125K | ﹤0.01% | 6175 |
|
|
2020
Q4 | $238K | Buy |
+14,386
| New | +$238K | ﹤0.01% | 5505 |
|